Table 2.

Pharmacological agents targeting the CX3CL1-CX3CR1 axis currently reported to be in development or clinical trials and disease of interest.

Product Name	Company/Institution	Class	Animal Models Reported	Human Trials In Progress/Planned
F1	INSERM	Modified CX3CR1 Ligand	Periodontitis	N/A
BI665088	Boehringer-Ingelheim/ Ablynx	VHH Antibody to CX3CR1	Atherosclerosis	Chronic Kidney Disease
E6011	Eisai Co	Humanised monoclonal Antibody	Pharmacokinetics in cynomolgus monkeys reported	Rheumatoid Arthritis Inflammatory Bowel Disease
AZD8797	Astra Zeneca	Small molecule inhibitor	Spinal Cord Injury Multiple Sclerosis	N/A
E6130	Eisai Co	Small Molecule Inhibitor	Inflammatory Bowel Disease	N/A
JMS 17-2	Drexel University College of Medicine	Small Molecule Inhibitor	Breast Cancer Metastasis	N/A

IMP, Investigational Medical Product; N/A, Not applicable; VHH, Variable Domain of Camelid, Heavy Chain Only.